Tempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer's Cancer Pipeline

MT Newswires Live05-14

Tempus AI (TEM) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.

Financial terms weren't disclosed.

Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.

The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.

Tempus' stock was up nearly 3% in recent Wednesday premarket activity.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2535275270?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2025-05-14 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535275270","market":"nz","top_or_hot":-1,"title":"Tempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer's Cancer Pipeline","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.</p><p>Financial terms weren't disclosed.</p><p>Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.</p><p>The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.</p><p>Tempus' stock was up nearly 3% in recent Wednesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer's Cancer Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer's Cancer Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-14 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.</p><p>Financial terms weren't disclosed.</p><p>Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.</p><p>The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.</p><p>Tempus' stock was up nearly 3% in recent Wednesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535275270","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535275270","pubTimestamp":1747229241,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempus AI  said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.Financial terms weren't disclosed.Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.Tempus' stock was up nearly 3% in recent Wednesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM.AU":"TEMPEST MINERALS LTD","BK4613":"AI应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","TEM":"Tempus AI","BK7095":"多种金属与采矿","BK4121":"生命科学工具和服务","BK4611":"AI医疗"},"translate_title":"Tempus AI与勃林格殷格翰合作推进勃林格癌症产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"TEM.AU":1},"content_text":"Tempus AI (TEM) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.Financial terms weren't disclosed.Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.Tempus' stock was up nearly 3% in recent Wednesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.6","shortVersion":"4.33.6","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535275270"}